Skip to content
Report cover - graphic representation of a target and the text reads: Tuberculosis Research Funding Trends, 2005-2022

2023 Report on TB Research Funding Trends

  • Dorrit Walsh
Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.
Read more

ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS

  • Dorrit Walsh
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
Read more
October 2023 TAGline cover: Lost in Translation. Features graphic of "TAG Translate" and shows 4 sets of terms: Shorter Treatments = Error: Insufficient Funding; Community Engagement = Error: political hostility; effective prevention = error inadequate awareness; broad screening = error: outdated guidelines

TAGline October 2023

  • Dorrit Walsh
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
Read more

TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline

  • Dorrit Walsh
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.
Read more

TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR

  • Dorrit Walsh
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.
Read more
Back To Top